Real-World Clinically-Relevant Toxicities of ALK TKIs in a Cohort of Patients With Advanced/Metastatic ALK plus NSCLC

Treatment with ALK-TKIs significantly prolongs overall survival (OS) in patients with ALK+ non-small cell lung cancer (NSCLC). Approximately 20-40% of patients experience adverse events (AEs) leading to dose reductions/temporary discontinuation in the published phase III trials and permanent treatment discontinuation due to toxicity in approximately 5-15%. Toxicity profiles of the different inhibitors overlap but some are also distinct. We describe rates of clinically-significant AEs and specific toxicity profiles in a real-world cohort of patients with ALK+ NSCLC.